The renin angiotenin aldosterone system (RAAS) is central to cardiovascular and renal physiology. However, there is no animal model in which the activation of the RAAS only reflects the activation of the angiotensin II (AngII) AT₁ receptor. As a first step to developing such a model, we characterized a gain-of-function mutant of the mouse AT_1A receptor. This mutant carries two mutations: N111S predicted to activate the receptor constitutively and a C-terminal deletion, 329, expected to reduce receptor internalization and desensitization. We expressed this double mutant (AT_1A-N111S/329) in heterologous cells. It showed a pharmacological profile consistent with that of other constitutively active mutants. Furthermore, it increased basal production of inositol phosphates (IP) as well as basal cytosolic and nuclear ERK activities. Basal proliferation of cells expressing the mutant was also greater than that of the wild type. The double mutant was poorly internalized and failed to recruit -arrestin 2 in the presence of AngII. It also showed hypersensitive and hyper-reactive responses to AngII for both IP production and ERK activation. The additivity of the phenotypes of the two mutations makes this mutant an appropriate candidate to test the physiological consequences of the AT₁ receptor activation itself in transgenic animal models.